Trials / Completed
CompletedNCT01071291
Effects of Niaspan™ on High-density Lipoprotein (HDL) in Healthy Male Subjects (0000-069)
A Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Evaluate the Effects of Niaspan™ on Reverse Cholesterol Transport in Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will evaluate whether chronic dosing with Niaspan™ increases reverse cholesterol transport, high-density lipoprotein cholesterol (HDL-C) levels, and fecal excretion of cholesterol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Niaspan | Niaspan™ |
| DRUG | Comparator: Placebo | Placebo |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2010-08-01
- Completion
- 2010-09-01
- First posted
- 2010-02-19
- Last updated
- 2015-10-12
Source: ClinicalTrials.gov record NCT01071291. Inclusion in this directory is not an endorsement.